Purpose The aim of the study was to compare plasma concentrations of rifampicin (RMP),
isoniazid (INH) and pyrazinamide (PZA) between tuberculosis (TB) patients with and without …

… Activity in anti-tuberculosis drug development has recently reached unprecedented levels, …
stage in the progress of new anti-tuberculosis drugs has consequently become a key issue for …

… of drug resistance. In summary, we found that the currently available first-line anti-tuberculosis
drugs … As many of these drugs were developed several decades ago, little research has …

… anti-tuberculosis drugs have been developed in the last 40 years or so, and that there is no
interest of the industry to invest and develop new drugs for … developed anti-tuberculosis drugs …

… Our findings of low anti-tuberculosis drug levels in children receiving standard short-course …
Data on anti-tuberculosis drug pharmacokinetics in children globally are limited, and there …

… The pathway to find a new TB drug, however, is arduous and … interested in anti-TB drug
development, which goes from … found along the TB drug development process and illustrates …

… pyrazinamide are the two drugs largely responsible for sterilizing activity during current
treatment. Pyrazinamide is unique amongst anti-tuberculosis drugs in having no genomic …

… We have developed a new and efficient method for anti-tuberculosis drug testing in vivo, …
to assess the preclinical efficacy of new drugs in animal models and enhance the progress of …

… of anti-tuberculosis drugs in the private sector in 17 low- and middle-income countries, and
explores whether substandard and falsified drugs may be exacerbating the problem of drug …

… Data on availability and cost of anti-tuberculosis (TB) drugs in relation to … drugs were not
available, we divided the cost of the fixed-dose combination (FDC) equally over the drugs that …